Saturday, 31 October 2026European Markets

KID And CAFOM Have A High Dividend Yield And Return On Equity In The Specialty Retail Industry.

Loading stream...

(vianews) - kid (kid.ol) is among this list of stock assets with the highest dividend rate and return on equity on the specialty retail industry.

financial asset price forward dividend yield return on equity
kid (kid.ol) kr128.40 7.23% 24.25%
cafom (cafo.pa) €8.98 2.33% 6.66%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. kid (kid.ol)

7.23% forward dividend yield and 24.25% return on equity

kid asa, together with its subsidiaries, operates as a home textile retailer in norway, sweden, finland, and estonia. it designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. the company provides its products under the kid, hemtex, dekosol, nordun, and premium collection brands. it also offers logistics services. the company was formerly known as nordisk tekstil holding as and changed its name to kid asa. kid asa was founded in 1937 and is headquartered in lier, norway.

earnings per share

as for profitability, kid has a trailing twelve months eps of kr5.89.

pe ratio

kid has a trailing twelve months price to earnings ratio of 21.8. meaning, the purchaser of the share is investing kr21.8 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.25%.

volume

today's last reported volume for kid is 12014 which is 89.93% below its average volume of 119420.

earnings before interest, taxes, depreciation, and amortization

kid's ebitda is 22.58.

growth estimates quarters

the company's growth estimates for the current quarter and the next is 49.6% and 14.4%, respectively.

sales growth

kid's sales growth is 6.4% for the present quarter and 6.5% for the next.

more news about kid.

2. cafom (cafo.pa)

2.33% forward dividend yield and 6.66% return on equity

centrale d'achat française pour l'outre-mer société anonyme provides home furnishing products in south-east asia, south america, europe, and middle east. the company offers household appliance products and services under darty; home equipment under but; design manufacturing under habitat; natural and wellness products under the nature & discoveries; furniture, decoration, and appliances under but cosy; and musical instruments under the music & sound brands in guadeloupe, french guiana, martinique, saint-martin, reunion island, and new caledonia. it also operates vente-unique.com, a b2c platform that engages in the online sale of furniture for individuals; and directlowcost.com that supplies furniture and decoration products for distribution professionals. the company was founded in 1985 and is based in paris, france.

earnings per share

as for profitability, cafom has a trailing twelve months eps of €1.33.

pe ratio

cafom has a trailing twelve months price to earnings ratio of 6.75. meaning, the purchaser of the share is investing €6.75 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.66%.

yearly top and bottom value

cafom's stock is valued at €8.98 at 01:40 est, way under its 52-week high of €10.50 and way above its 52-week low of €7.70.

more news about cafom.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com